← Back to Patent Explorer
US4698420A Expired / Lapsed US ⏱️ 0.0 years remaining

Antibody hybrid molecules and process for their preparation

Assignee: Xoma Royalty Corp
•
Filing: 1985-02-25
•
Granted: 1987-10-06
•
Expires: 2005-02-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Antibodies which contain reduced sulfhydryl groups in proximity of the carboxyl terminal end of their heavy chain are coupled to another moiety which has an available sulfhydryl for forming a disulfide bond with the antibodies. IgM is a typical antibody which contains a suitable structure by virtue of its cysteine residue in proximity to the carboxyl terminal end of its heavy chain. A typical hybrid is formed with IgM and the A chain of a toxin such as ricin by the formation of a covalent disulfide bond therebetween. Use of antibodies having structures such as IgM result in hybrid formation in which the moiety joined to the antibody is site directed with respect to its bonding location on the antibody. Such hybrids have utility including in vivo therapeutic applications in which the functionality of the antibody is not deleteriously impaired by the moiety bonded thereto.

Inventors

  • 👤 Howard B. Urnovitz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 09:54
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; Y; Y10; Y10S; Y10S424/00; Y10S424/804; Y10S424/806; Y10S424/807; Y10S530/00; Y10S530/861; Y10S530/863; Y10S530/864

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 152 words
A method for preparing an antibody hybrid molecule by forming a covalent disulfide bond between a sulfhydryl group on an organic moiety and a intermolecular sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of the monomeric form of an antibody of class IgA of IgM, said method comprising the steps of: (1) selecting an polymeric antibody of interest, said antibody selected from the group consisting of class IgA or IgM antibodies; (2) activating a sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of the monomeric form of said anitbody by mild reduction, wherein the mild reduction breaks a intermolecular polymer-forming disulfide bond without breaking intramolecular bonds; and (3) conjugating said antibody monomer to a moiety of interest by way of a disulfide bond consisting essentially of a bond formed between said activated sulfhydryl group and a free sulfhydryl group on said moiety.
Claim 2
Independent Claim 152 words
A method for preparing an antibody hybrid molecule by forming a covalent disulfide bond between a sulfhydryl group on an organic moiety and a intermolecular sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of the monomeric form of an antibody of class IgA of IgM, said method comprising the steps of: (1) selecting an polymeric antibody of interest, said antibody selected from the group consisting of class IgA or IgM antibodies; (2) activating a sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of the monomeric form of said anitbody by mild reduction, wherein the mild reduction breaks a intermolecular polymer-forming disulfide bond without breaking intramolecular bonds; and (3) conjugating said antibody monomer to a moiety of interest by way of a disulfide bond consisting essentially of a bond formed between said activated sulfhydryl group and a free sulfhydryl group on said moiety.
Claim 3
Dependent Claim 22 words
A method according to claim 1, wherein said mild reduction is accomplished by exposing said polymeric antibody to a concentration of dithiothreitol.
Claim 4
Dependent Claim 15 words
A method according to claim 2, wherein said concentration of dithiothreitol is 2mM to 10mM.
Claim 5
Dependent Claim 22 words
A method according to claim 2, wherein said polymeric antibody is exposed to said concentration of dithiothreitol in the presence of nitrogen.
Claim 6
Dependent Claim 22 words
A method according to claim 1, wherein said mild reduction is accomplished by exposing said polymeric antibody to a concentration of mercaptoethanol.
Claim 7
Dependent Claim 22 words
A method according to claim 1, wherein said mild reduction is accomplished by exposing said polymeric antibody to a concentration of cysteine.
Claim 8
Dependent Claim 20 words
A method according to claim 1, wherein said organic moiety is selected from toxins, labeled proteins, antibodies and chemotherapeutic drugs.
Claim 9
Dependent Claim 15 words
A method according to claim 1, wherein said organic moiety is a radio labeled protein.
Claim 10
Dependent Claim 17 words
A method according to claim 1, wherein said organic moiety is the A chain of a toxin.
Claim 11
Dependent Claim 14 words
A method according to claim 9, wherein said A chain is ricin A chain.
Claim 12
Dependent Claim 64 words
An antibody hybrid comprising an organic moiety and an antibody monomer of class IgA or IgM, wherein said organic moiety is bound to said antibody monomer by a disulfide bond consisting essentially of a bond formed between an activated intermolecular sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of said antibody and a free sulfhydryl group on said moiety.
Claim 13
Dependent Claim 64 words
An antibody hybrid comprising an organic moiety and an antibody monomer of class IgA or IgM, wherein said organic moiety is bound to said antibody monomer by a disulfide bond consisting essentially of a bond formed between an activated intermolecular sulfhydryl group found on the carboxyl terminal cysteine residue of the heavy chain of said antibody and a free sulfhydryl group on said moiety.
Claim 14
Dependent Claim 19 words
An antibody hybrid according to claim 11, wherein said hybrid is produced by the method according to claim 1.
Claim 15
Dependent Claim 20 words
A hybrid according to claim 11, wherein said organic moiety is selected from toxins, ladeled proteins, antibodies and chemotherapeutic drugs.
Claim 16
Dependent Claim 15 words
A hybrid according to claim 11, wherein said organic moiety is a radio labeled protein.
Claim 17
Dependent Claim 17 words
A hybrid according to claim 11, wherein said organic moiety is the A chain of a toxin.
Claim 18
Dependent Claim 14 words
A hybrid according to claim 15, wherein said A chain is ricin A chain.

References Cited (Backward Citations)

US4340535A Cited
US4350626A Cited
US4379145A Cited
US4350236A Cited
US4368149A Cited
US4489710A Cited
EP0080401A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-10-05 1991-04-06 1991-10-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-10-05 1995-04-06 1995-10-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-10-05 1999-04-06 1999-10-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag